MFN carve-outs come into focus

The Trump administration and pharmaceutical companies have kept the terms of their “most favored nation” agreements secret, but some details are starting to emerge about deals reached by smaller companies.

In contrast to the larger companies, some of the mid-tier biopharmas appear to have avoided pledges to prospectively benchmark new drug prices to an MFN reference, and at least one has negotiated a blanket exemption for products that are only indicated for rare conditions...